Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland

Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C.

or a number of years, immunologists have strived to Funderstand the mechanisms associated with treatment-induced eradication of hepatitis C virus (HCV). However, interferon (IFN)-a–based therapies did not allow studies examining the role of the virus itself on innate and adaptive immunity to HCV. The study by Serti et al published in this issue of Gastroenterology provides a unique opportunity ...

Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C

BACKGROUND There is a lack of evidence-based data on aged patients with newer direct-acting antivirals (DAAs) and with shorter duration of treatment regimens involving DAAs with or without ribavirin (RBV) and pegylated interferon (Peg IFN). PATIENTS AND METHODS Medical records of 240 patients treated with DAAs with or without Peg IFN and RBV between January 2013 and July 2015 were retrospecti...

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome

Patients with Down syndrome who received blood transfusions, likely in conjunction with cardiothoracic surgery for congenital heart disease and prior to the implementation of blood-donor screening for hepatitis C virus infection, face a substantial risk of acquiring the infection. In the past, interferon-based therapy for chronic hepatitis C infection in patients with Down syndrome was noted to...

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

BACKGROUND Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy. Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper provides a review of the neuropsych...

Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.